Compare · CERS vs DXCM

CERS vs DXCM

Side-by-side comparison of Cerus Corporation (CERS) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CERS and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $30.44B, about 81.2x CERS ($374.7M).
  • Over the past year, CERS is up 21.6% and DXCM is up 39.6% - DXCM leads by 18.1 points.
  • DXCM has been more active in the news (13 items in the past 4 weeks vs 7 for CERS).
  • DXCM has more recent analyst coverage (25 ratings vs 4 for CERS).
PerformanceCERS+24.41%DXCM+39.65%
2025-11-18+0.00%2026-11-17
MetricCERSDXCM
Company
Cerus Corporation
DexCom Inc.
Price
-
-
Market cap
$374.7M
$30.44B
1M return
-16.40%
-5.10%
1Y return
+21.57%
+39.65%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
1997
2005
News (4w)
7
13
Recent ratings
4
25
CERS

Cerus Corporation

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.

DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Latest CERS

Latest DXCM